Naturally improving insulin resistance with amorfrutins

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 19, 2012, Pages 7136-7137

  Lefebvre, Philippe ^a   Staels, Bart ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMORFRUTIN 1; ANTIDIABETIC AGENT; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ADIPOCYTE; AMORPHA FRUTICOSA; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; DRUG MEGADOSE; DYSLIPIDEMIA; ENERGY EXPENDITURE; FABACEAE; GLUCOSE BLOOD LEVEL; GLYCYRRHIZA; GLYCYRRHIZA FOETIDA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIGAND BINDING; LIPID DIET; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; BIOLOGICAL AGENTS; DIABETES MELLITUS, TYPE 2; FABACEAE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; SALICYLIC ACIDS;

EID: 84860794310     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1204455109     Document Type: Note

References (27)

1. Nolan CJ, Damm P, Prentki M (2011) Type 2 diabetes across generations: From pathophysiology to prevention and management. Lancet 378:169-181.
2. Plutzky J (2011) Macrovascular effects and safety issues of therapies for type 2 diabetes. Am J Cardiol 108(3, suppl)25B-32B.
3. Zarich SW (2009) Antidiabetic agents and cardiovascular risk in type 2 diabetes. Nat Rev Endocrinol 5: 500-506.
4. DeFronzo RA, Abdul-Ghani M (2011) Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 34(suppl 2):S202-S209.
5. Weidner C, et al. (2012) Amorfrutins are potent anti-diabetic dietary natural products. Proc Natl Acad Sci USA 109:7257-7262.
6. Lehmann JM, et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
7. DeFronzo RA (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009. Diabetologia 53: 1270-1287.
8. Sugii S, et al. (2009) PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization. Proc Natl Acad Sci USA 106:22504-22509.
9. Gray SL, Vidal-Puig AJ (2007) Adipose tissue expandability in the maintenance of metabolic homeostasis. Nutr Rev 65:S7-S12.
10. Hevener AL, et al. (2007) Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 117:1658-1669. (Pubitemid 46871350)
11. Lu M, et al. (2011) Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 17:618-622.
12. Nissen SE, Wolski K (2010) Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170: 1191-1201.
13. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive Investigators (2009) Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive. Drug Saf 32:187-202.
14. Bloomgarden ZT (2011) Type 2 diabetes: Uses of thiazolidinediones and insulin. Diabetes Care 34:e11-e16.
15. Doshi LS, Brahma MK, Bahirat UA, Dixit AV, Nemmani KV (2010) Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. Expert Opin Investig Drugs 19: 489-512.
16. Rocchi S, et al. (2001) A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8:737-747. (Pubitemid 33030208)
17. Carmona MC, et al. (2007) S 26948, a new specific PPARγ modulator (SPPARM) with potent antidiabetic and antiatherogenic effects. Diabetes 56:2797-2808. (Pubitemid 350044924)
18. Allen T, et al. (2006) Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes 55:2523-2533. (Pubitemid 44871152)
19. Lefebvre B, et al. (2010) Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans. J Clin Invest 120:1454-1468.
20. Choi JH, et al. (2011) Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477:477-481.
21. Dutchak PA, et al. (2012) Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 148:556-567.
22. Tailleux A, Wouters K, Staels B (2011) Roles of PPARs in NAFLD: Potential therapeutic targets. Biochim Biophys Acta 1821:809-818.
23. Li P, et al. (2011) Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity. Cell 147:815-826.
24. Staels B (2005) Fluid retention mediated by renal PPAR-gamma. Cell Metab 2:77-78.
25. Dat NT, et al. (2008) Phenolic constituents of Amorpha fruticosa that inhibit NF-kappaB activation and related gene expression. J Nat Prod 71:1696-1700.
26. National Center for Biotechnology Information PubChem BioAssay Database. Available at: http://pubchem.ncbi.nlm. nih.gov/summary/summary.cgi?cid= 17950432&loc=ec-rcs. Accessed March 26, 2012.
27. Colca JR, et al. (2004) Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286:E252-E260. (Pubitemid 38140317)